[50 years of systemic therapy of urinary bladder cancer].
[50 years of systemic therapy of urinary bladder cancer].
Aktuelle Urol. 2019 Jun 26;:
Authors: Retz M, von Amsberg G, Horn T, Gschwend JE, Maisch P
Abstract
This review summarises the treatment strategies of the last five decades for metastatic urothelial cancer. The introduction of combination chemotherapy in the mid-1980s led to clinically significant response rates and prolonged survival. Two years ago, the results of a phase-3 clinical trial with the PD1 inhibitor pembrolizumab for second-line treatment of metastatic urothelial carcinoma were published. These data were the first to show an overall survival benefit in comparison with a conventional chemotherapy with vinflunine, docetaxel or paclitaxel. Currently, PD1/PD-L1 inhibitors are also tested within randomized phase-3-trials for first-line treatment using different approaches either as a monotherapy or a combination with conventional chemotherapy or CTLA-4 inhibitors. Whereas data from single-arm phase-2 clinical trials have already been published, first phase-3 data are expected in 2019.
PMID: 31242517 [PubMed - as supplied by publisher]
Source: Aktuelle Urologie - Category: Urology & Nephrology Authors: Retz M, von Amsberg G, Horn T, Gschwend JE, Maisch P Tags: Aktuelle Urol Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Docetaxel | Taxotere | Urology & Nephrology